Subcutaneous delivery of hyaluronidase may boost effectiveness of cancer immunotherapy
Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way anti-cancer immunotherapy is administered from intravenous administration to subcutaneous administration ...
Jan 28, 2026
0
11









